Weekly Recap: A Few of Our Latest Trades in Healthcare
Long Ideas - For those that missed it last week, Dr. Chaudhry offered an educational, retrospective look at both AVEO and DCTH’s advisory panel votes. In addition, we … Continue Reading
Read nowAuthor Archives: Editorial Staff
PropThink’s Biotech Longs and Shorts this Week
Long Ideas - This week was dominated by a number of binary events (which we outlined on Monday), two of which played out against us; Dr. Chaudhry expected that … Continue Reading
Read nowBinary Events Abound in Biotech
Long Ideas - As most biotech enthusiasts will be well-aware of, biotech is rife with binary events this week, many of which fall on Tuesday April 30. While … Continue Reading
Read nowThe PropThink Recap: Finding Value in Biotech
Long Ideas - Synergy’s equity financing, which wrapped up last Tuesday, put the company in a strong position for a partnership (or M&A) negotiation regarding plecanatide. The stock … Continue Reading
Read nowPropThink’s Biotech Roundup
Long Ideas - ICPT has a big problem, and could be headed back to its post-IPO prices, 50% lower than where they trade today. The company piqued our … Continue Reading
Read now
Keryx, Zerenex, and IP Protection: A PropThink Conference Call
Interviews - On April 11, PropThink hosted an Interview and Q&A (via conference call) for PropThink subscribers with Dr. Scott Chambers, a leading patent attorney and former … Continue Reading
Read nowPropThink’s Week in the Life Sciences
Most Popular - Keryx (KERX) has come back under the magnifying glass at PropThink. We hosted Dr. Scott Chambers, a patent attorney and former USPTO staff, on a … Continue Reading
Read now